839 Shares in Qiagen (NYSE:QGEN) Bought by Park Place Capital Corp

Park Place Capital Corp bought a new stake in Qiagen (NYSE:QGEN) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 839 shares of the company’s stock, valued at approximately $36,000.

A number of other institutional investors also recently modified their holdings of QGEN. Norges Bank bought a new position in shares of Qiagen in the fourth quarter worth about $264,322,000. Wellington Management Group LLP increased its stake in shares of Qiagen by 81.0% in the third quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company’s stock valued at $245,299,000 after buying an additional 2,709,030 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Qiagen by 8.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock valued at $1,045,211,000 after buying an additional 1,809,486 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Qiagen by 33,220.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company’s stock valued at $58,435,000 after buying an additional 1,341,450 shares during the period. Finally, Nuance Investments LLC acquired a new stake in Qiagen during the 4th quarter valued at approximately $47,479,000. Institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Thursday, June 27th. Stifel Nicolaus decreased their target price on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.05.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $40.23 on Tuesday. The company has a current ratio of 1.84, a quick ratio of 1.45 and a debt-to-equity ratio of 0.25. The stock’s fifty day simple moving average is $43.21 and its two-hundred day simple moving average is $43.54. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.70. The stock has a market cap of $9.18 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.18 and a beta of 0.40.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The firm had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same period last year, the firm posted $0.53 EPS. The business’s revenue was down 5.4% compared to the same quarter last year. As a group, analysts forecast that Qiagen will post 2.13 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.